Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Editorial: Pitfalls in the Neuro-Imaging of Glioblastoma in the Era of Antiangiogenic and Immune-Targeted Therapy-Detecting Elusive Disease, Defining Response.

New PZ, Rosenfeld MR.

Front Neurol. 2017 Jul 3;8:311. doi: 10.3389/fneur.2017.00311. eCollection 2017. No abstract available.

2.

Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response.

Huang RY, Neagu MR, Reardon DA, Wen PY.

Front Neurol. 2015 Feb 23;6:33. doi: 10.3389/fneur.2015.00033. eCollection 2015. Review.

3.

Commentary: Pitfalls in the Neuroimaging of Glioblastoma in the Era of Antiangiogenic and Immuno/Targeted Therapy.

Skolnik AD, Wang S, Gopal PP, Mohan S.

Front Neurol. 2018 Feb 5;9:51. doi: 10.3389/fneur.2018.00051. eCollection 2018. No abstract available.

4.

Individualized targeted therapy for glioblastoma: fact or fiction?

Weller M, Stupp R, Hegi M, Wick W.

Cancer J. 2012 Jan-Feb;18(1):40-4. doi: 10.1097/PPO.0b013e318243f6c9. Review.

PMID:
22290256
5.

Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients.

Hutterer M, Hattingen E, Palm C, Proescholdt MA, Hau P.

Neuro Oncol. 2015 Jun;17(6):784-800. doi: 10.1093/neuonc/nou322. Epub 2014 Dec 27. Review.

6.

Complementary information from magnetic resonance imaging and (18)F-fluoromisonidazole positron emission tomography in the assessment of the response to an antiangiogenic treatment in a rat brain tumor model.

Valable S, Petit E, Roussel S, Marteau L, Toutain J, Divoux D, Sobrio F, Delamare J, Barré L, Bernaudin M.

Nucl Med Biol. 2011 Aug;38(6):781-93. doi: 10.1016/j.nucmedbio.2011.01.010. Epub 2011 Apr 21.

PMID:
21843775
7.

Amyloidoma presenting as a butterfly glioma on positron emission tomography scan and magnetic resonance-spectroscopy: a case report and review of the literature.

Sin AH, Gonzalez-Toledo E, Fowler M, Minagar A, Nanda A.

J La State Med Soc. 2008 Jan-Feb;160(1):44-7, 49-50. Review.

PMID:
18669409
8.

Post-treatment appearances, pitfalls, and patterns of failure in head and neck cancer on FDG PET/CT imaging.

Purandare NC, Puranik AD, Shah S, Agrawal A, Rangarajan V.

Indian J Nucl Med. 2014 Jul;29(3):151-7. doi: 10.4103/0972-3919.136564.

9.

Diagnosis and Management of Spinal Metastasis of Glioblastoma.

Tai P, Dubey A, Salim M, Vu K, Koul R.

Can J Neurol Sci. 2015 Nov;42(6):410-3. doi: 10.1017/cjn.2015.285. Epub 2015 Aug 27.

PMID:
26310615
10.

High-grade glioma radiation therapy target volumes and patterns of failure obtained from magnetic resonance imaging and 18F-FDOPA positron emission tomography delineations from multiple observers.

Kosztyla R, Chan EK, Hsu F, Wilson D, Ma R, Cheung A, Zhang S, Moiseenko V, Benard F, Nichol A.

Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):1100-6. doi: 10.1016/j.ijrobp.2013.09.008. Epub 2013 Oct 22.

PMID:
24161427
11.
12.

Diagnostic accuracy of serial CT/magnetic resonance imaging review vs. positron emission tomography/CT in colorectal cancer patients with suspected and known recurrence.

Potter KC, Husband JE, Houghton SL, Thomas K, Brown G.

Dis Colon Rectum. 2009 Feb;52(2):253-9. doi: 10.1007/DCR.0b013e31819d11e6.

PMID:
19279420
13.

Assessing the response to targeted therapies in renal cell carcinoma: technical insights and practical considerations.

Bex A, Fournier L, Lassau N, Mulders P, Nathan P, Oyen WJ, Powles T.

Eur Urol. 2014 Apr;65(4):766-77. doi: 10.1016/j.eururo.2013.11.031. Epub 2013 Nov 28. Review.

PMID:
24341958
14.

[Use of the functional imaging modalities in radiation therapy treatment planning in patients with glioblastoma].

Dhermain F, Ducreux D, Bidault F, Bruna A, Parker F, Roujeau T, Beaudre A, Armand JP, Haie-Meder C.

Bull Cancer. 2005 Apr;92(4):333-42. Review. French.

15.
16.
17.

Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.

Sadowski SM, Neychev V, Millo C, Shih J, Nilubol N, Herscovitch P, Pacak K, Marx SJ, Kebebew E.

J Clin Oncol. 2016 Feb 20;34(6):588-96. doi: 10.1200/JCO.2015.64.0987. Epub 2015 Dec 28.

18.
19.

Impact of [11C]methionine positron emission tomography for target definition of glioblastoma multiforme in radiation therapy planning.

Matsuo M, Miwa K, Tanaka O, Shinoda J, Nishibori H, Tsuge Y, Yano H, Iwama T, Hayashi S, Hoshi H, Yamada J, Kanematsu M, Aoyama H.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):83-9. doi: 10.1016/j.ijrobp.2010.09.020. Epub 2010 Nov 20.

PMID:
21095072
20.

Positron Emission Tomography/Magnetic Resonance Imaging for Local Tumor Staging in Patients With Primary Breast Cancer: A Comparison With Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging.

Grueneisen J, Nagarajah J, Buchbender C, Hoffmann O, Schaarschmidt BM, Poeppel T, Forsting M, Quick HH, Umutlu L, Kinner S.

Invest Radiol. 2015 Aug;50(8):505-13. doi: 10.1097/RLI.0000000000000197.

PMID:
26115367

Supplemental Content

Support Center